Tricida Inc (1T7)

Frankfurt
Currency in EUR
Disclaimer
0.030
0.000
(0.00%)
Closed
Day's Range
0.030
0.055
52 wk Range
0.025
13.510
Volume
0
Prev. Close
0.036
Open
0.05
Day's Range
0.03-0.055
52 wk Range
0.025-13.51
Volume
0
Average Vol. (3m)
13,654
1-Year Change
-99.59%
Shares Outstanding
58,028,254
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

0.75
MYO
0.00%
0.57
DATS
+7.72%
0.29
MDVL
-10.02%
0.400
VCNX
-5.38%
2.71
NOGN
-25.21%

Tricida Inc News

Tricida Inc Analysis

Tricida Inc Company Profile

Tricida, Inc. is a pharmaceutical company, which is focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101). TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The Company's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.